TY  - JOUR

T1  - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.

JO  - Health Technoogyl Assessment

UR  - https://eprints.whiterose.ac.uk/id/eprint/100350

UR  - http://dx.doi.org/10.3310/hta20390

PY  - 2016/05/01

AU  - Archer R

AU  - Tappenden P

AU  - Ren S

AU  - Martyn-St James M

AU  - Harvey R

AU  - Basarir H

AU  - Stevens J

AU  - Carroll C

AU  - Cantrell A

AU  - Lobo A

AU  - Hoque S

ED  - 

DO  - DOI: 10.3310/hta20390

PB  - NIHR Health Technology Assessment Programme

VL  - 20

Y2  - 2025/10/31

ER  -